Benzimidazole and Its Derivatives As Cancer Therapeutics: The Potential Role from Traditional to Precision Medicine

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2023 Mar 6

PMID 36873180

Authors

Yeuan Ting Lee

Yi Jer Tan

Chern Ein Oon

Affiliations

Soon will be listed here.

Abstract

Cancer is the second leading cause of mortality globally which remains a continuing threat to human health today. Drug insensitivity and resistance are critical hurdles in cancer treatment; therefore, the development of new entities targeting malignant cells is considered a high priority. Targeted therapy is the cornerstone of precision medicine. The synthesis of benzimidazole has garnered the attention of medicinal chemists and biologists due to its remarkable medicinal and pharmacological properties. Benzimidazole has a heterocyclic pharmacophore, which is an essential scaffold in drug and pharmaceutical development. Multiple studies have demonstrated the bioactivities of benzimidazole and its derivatives as potential anticancer therapeutics, either through targeting specific molecules or non-gene-specific strategies. This review provides an update on the mechanism of actions of various benzimidazole derivatives and the structure‒activity relationship from conventional anticancer to precision healthcare and from bench to clinics.

Citing Articles

Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article.

Wagih N, Abdel-Rahman I, El-Koussi N, Abuo-Rahma G RSC Adv. 2025; 15(2):966-1010.

PMID: 39807197 PMC: 11726184. DOI: 10.1039/d4ra05014b.

Apoptotic cell death of stomach cancer lines (AGS) induced by Co-NTB complex through cellular organelles and DNA damage.

Balusamy S, Balamurugan M, Purushothaman S, Somasundaram S, Elsadek M, Sohn D RSC Adv. 2025; 15(2):739-747.

PMID: 39802467 PMC: 11711993. DOI: 10.1039/d4ra06377e.

Novel bis-benzimidazole-triazole hybrids: anticancer study, in silico approaches, and mechanistic investigation.

Soliman M, Ahmed H, Eltamany E, Boraei A, Aljuhani A, Salama S Future Med Chem. 2024; 17(1):93-107.

PMID: 39670306 PMC: 11702989. DOI: 10.1080/17568919.2024.2437980.

N-Aryl Benzimidazole and Benzotriazole Derivatives and Their Hybrids as Cytotoxic Agents: Design, Synthesis and Structure-Activity Relationship Studies.

Aleksandrova Y, Nikolaeva N, Shagina I, Smirnova K, Zubishina A, Khlopotinin A Molecules. 2024; 29(22).

PMID: 39598749 PMC: 11596563. DOI: 10.3390/molecules29225360.

Cu(II) complexes based on benzimidazole ligands: synthesis, characterization, DFT, molecular docking & bioactivity study.

Hamali M, Roney M, Dubey A, Uddin M, Zulkifli N, Mohd Aluwi M Future Med Chem. 2024; 16(23):2535-2546.

PMID: 39530504 PMC: 11622761. DOI: 10.1080/17568919.2024.2419353.

References

Khattab M, Al-Karmalawy A . Revisiting Activity of Some Nocodazole Analogues as a Potential Anticancer Drugs Using Molecular Docking and DFT Calculations. Front Chem. 2021; 9:628398. PMC: 8024586. DOI: 10.3389/fchem.2021.628398. View

Saunders L, Verdin E . Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007; 26(37):5489-504. DOI: 10.1038/sj.onc.1210616. View

Bleach R, McIlroy M . The Divergent Function of Androgen Receptor in Breast Cancer; Analysis of Steroid Mediators and Tumor Intracrinology. Front Endocrinol (Lausanne). 2018; 9:594. PMC: 6213369. DOI: 10.3389/fendo.2018.00594. View

Marks P, Xu W . Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4):600-8. PMC: 2766855. DOI: 10.1002/jcb.22185. View

Ricciardelli C, Bianco-Miotto T, Jindal S, Butler L, Leung S, McNeil C . The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clin Cancer Res. 2018; 24(10):2328-2341. DOI: 10.1158/1078-0432.CCR-17-1199. View

Al-Mudaris Z, Majid A, Ji D, Al-Mudarris B, Chen S, Liang P . Conjugation of benzylvanillin and benzimidazole structure improves DNA binding with enhanced antileukemic properties. PLoS One. 2013; 8(11):e80983. PMC: 3829952. DOI: 10.1371/journal.pone.0080983. View

Bhaduri S, Ranjan N, Arya D . An overview of recent advances in duplex DNA recognition by small molecules. Beilstein J Org Chem. 2018; 14:1051-1086. PMC: 6009268. DOI: 10.3762/bjoc.14.93. View

Palma J, Wang Y, Rodriguez L, Montgomery D, Ellis P, Bukofzer G . ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009; 15(23):7277-90. DOI: 10.1158/1078-0432.CCR-09-1245. View

Raimondi M, Randazzo O, La Franca M, Barone G, Vignoni E, Rossi D . DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents. Molecules. 2019; 24(6). PMC: 6471984. DOI: 10.3390/molecules24061140. View

10.

Davey R, Grossmann M . Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016; 37(1):3-15. PMC: 4810760. View

11.

Molehin D, Rasha F, Layeequr Rahman R, Pruitt K . Regulation of aromatase in cancer. Mol Cell Biochem. 2021; 476(6):2449-2464. DOI: 10.1007/s11010-021-04099-0. View

12.

Tran B, Cohen M . The discovery and development of binimetinib for the treatment of melanoma. Expert Opin Drug Discov. 2020; 15(7):745-754. PMC: 7539481. DOI: 10.1080/17460441.2020.1746265. View

13.

Corona S, Generali D . Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther. 2018; 12:321-330. PMC: 5818877. DOI: 10.2147/DDDT.S137783. View

14.

Bates D, Eastman A . Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol. 2016; 83(2):255-268. PMC: 5237681. DOI: 10.1111/bcp.13126. View

15.

Hontecillas-Prieto L, Flores-Campos R, Silver A, de Alava E, Hajji N, Garcia-Dominguez D . Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. Front Genet. 2020; 11:578011. PMC: 7516260. DOI: 10.3389/fgene.2020.578011. View

16.

Desai N, Shihory N, Kotadiya G, Desai P . Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs. Eur J Med Chem. 2014; 82:480-9. DOI: 10.1016/j.ejmech.2014.06.004. View

17.

Tong Y, Bouska J, Ellis P, Johnson E, Leverson J, Liu X . Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. J Med Chem. 2009; 52(21):6803-13. DOI: 10.1021/jm900697r. View

18.

Hasinoff B, Wu X, Nitiss J, Kanagasabai R, Yalowich J . The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol. 2012; 84(12):1617-26. PMC: 3501595. DOI: 10.1016/j.bcp.2012.09.023. View

19.

Matsuba Y, Edatsugi H, Mita I, Matsunaga A, Nakanishi O . A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism. Cancer Chemother Pharmacol. 2000; 46(1):1-9. DOI: 10.1007/s002800000120. View

20.

Rumpf T, Schiedel M, Karaman B, Roessler C, North B, Lehotzky A . Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat Commun. 2015; 6:6263. PMC: 4339887. DOI: 10.1038/ncomms7263. View